Literature DB >> 29132714

PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies.

Steven P Rowe1, Kenneth J Pienta2, Martin G Pomper3, Michael A Gorin3.   

Abstract

The use of [18F]- and [68Ga]-labeled inhibitors of prostate-specific membrane antigen (PSMA) for positron emission tomography (PET) imaging of prostate cancer is now widespread. We have proposed a reporting and data system called PSMA-RADS version 1.0, which is a framework for classifying PSMA-targeted PET scans and individual findings into categories that reflect the likelihood of the presence of prostate cancer.
Copyright © 2017 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29132714      PMCID： PMC6859641          DOI： 10.1016/j.eururo.2017.10.027

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  11 in total

1.  [68Ga]Gallium-labelled PSMA ligand as superior PET tracer for the diagnosis of prostate cancer: comparison with 18F-FECH.

Authors:  A Afshar-Oromieh; U Haberkorn; M Eder; M Eisenhut; C M Zechmann
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-02-04       Impact factor: 9.236

2.  Radiologists May Now Be Accountable for Containing Medicare Costs and Spending Under MACRA.

Authors:  Andrew B Rosenkrantz; Joshua A Hirsch; Ezequiel Silva; Gregory N Nicola
Journal:  J Am Coll Radiol       Date:  2017-04-14       Impact factor: 5.532

3.  Proposal for a Structured Reporting System for Prostate-Specific Membrane Antigen-Targeted PET Imaging: PSMA-RADS Version 1.0.

Authors:  Steven P Rowe; Kenneth J Pienta; Martin G Pomper; Michael A Gorin
Journal:  J Nucl Med       Date:  2017-09-08       Impact factor: 10.057

4.  BI-RADS categorization as a predictor of malignancy.

Authors:  S G Orel; N Kay; C Reynolds; D C Sullivan
Journal:  Radiology       Date:  1999-06       Impact factor: 11.105

5.  "Gotta Catch 'em All", or Do We? Pokemet Approach to Metastatic Prostate Cancer.

Authors:  Declan G Murphy; Christopher J Sweeney; Bertrand Tombal
Journal:  Eur Urol       Date:  2017-03-07       Impact factor: 20.096

6.  Correlation of PSMA-Targeted 18F-DCFPyL PET/CT Findings With Immunohistochemical and Genomic Data in a Patient With Metastatic Neuroendocrine Prostate Cancer.

Authors:  Jeffrey J Tosoian; Michael A Gorin; Steven P Rowe; Darian Andreas; Zsolt Szabo; Kenneth J Pienta; Martin G Pomper; Tamara L Lotan; Ashley E Ross
Journal:  Clin Genitourin Cancer       Date:  2016-09-19       Impact factor: 2.872

7.  Imaging of metastatic clear cell renal cell carcinoma with PSMA-targeted ¹⁸F-DCFPyL PET/CT.

Authors:  Steven P Rowe; Michael A Gorin; Hans J Hammers; M Som Javadi; Hazem Hawasli; Zsolt Szabo; Steve Y Cho; Martin G Pomper; Mohamad E Allaf
Journal:  Ann Nucl Med       Date:  2015-08-19       Impact factor: 2.668

8.  LI-RADS: a case-based review of the new categorization of liver findings in patients with end-stage liver disease.

Authors:  Andrei S Purysko; Erick M Remer; Christopher P Coppa; Hilton M Leão Filho; Chakradhar R Thupili; Joseph C Veniero
Journal:  Radiographics       Date:  2012 Nov-Dec       Impact factor: 5.333

9.  Biodistribution, tumor detection, and radiation dosimetry of 18F-DCFBC, a low-molecular-weight inhibitor of prostate-specific membrane antigen, in patients with metastatic prostate cancer.

Authors:  Steve Y Cho; Kenneth L Gage; Ronnie C Mease; Srinivasan Senthamizhchelvan; Daniel P Holt; Akimosa Jeffrey-Kwanisai; Christopher J Endres; Robert F Dannals; George Sgouros; Martin Lodge; Mario A Eisenberger; Ronald Rodriguez; Michael A Carducci; Camilo Rojas; Barbara S Slusher; Alan P Kozikowski; Martin G Pomper
Journal:  J Nucl Med       Date:  2012-12       Impact factor: 10.057

Review 10.  Pearls and pitfalls in clinical interpretation of prostate-specific membrane antigen (PSMA)-targeted PET imaging.

Authors:  Sara Sheikhbahaei; Ali Afshar-Oromieh; Matthias Eiber; Lilja B Solnes; Mehrbod S Javadi; Ashley E Ross; Kenneth J Pienta; Mohamad E Allaf; Uwe Haberkorn; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-08-01       Impact factor: 9.236
View more
  28 in total

1.  Interobserver Agreement for the Standardized Reporting System PSMA-RADS 1.0 on 18F-DCFPyL PET/CT Imaging.

Authors:  Rudolf A Werner; Ralph A Bundschuh; Lena Bundschuh; Mehrbod S Javadi; Jeffrey P Leal; Takahiro Higuchi; Kenneth J Pienta; Andreas K Buck; Martin G Pomper; Michael A Gorin; Constantin Lapa; Steven P Rowe
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

2.  Follow-up of Lesions with Equivocal Radiotracer Uptake on PSMA-Targeted PET in Patients with Prostate Cancer: Predictive Values of the PSMA-RADS-3A and PSMA-RADS-3B Categories.

Authors:  Yafu Yin; Rudolf A Werner; Takahiro Higuchi; Constantin Lapa; Kenneth J Pienta; Martin G Pomper; Michael A Gorin; Steven P Rowe
Journal:  J Nucl Med       Date:  2018-09-06       Impact factor: 10.057

3.  [68Ga]Ga-PSMA-11 in prostate cancer: a comprehensive review.

Authors:  Frédéric Bois; Camille Noirot; Sébastien Dietemann; Ismini C Mainta; Thomas Zilli; Valentina Garibotto; Martin A Walter
Journal:  Am J Nucl Med Mol Imaging       Date:  2020-12-15

4.  Prostate Specific Antigen and Prostate Specific Antigen Doubling Time Predict Findings on 18F-DCFPyL Positron Emission Tomography/Computerized Tomography in Patients with Biochemically Recurrent Prostate Cancer.

Authors:  Michael A Gorin; Steven P Rowe; Mark C Markowski; Ramy Sedhom; Wei Fu; Javaughn Corey R Gray; Mario A Eisenberger; Martin G Pomper; Kenneth J Pienta
Journal:  J Urol       Date:  2020-04-06       Impact factor: 7.450

5.  Detection of Early Progression with 18F-DCFPyL PET/CT in Men with Metastatic Castration-Resistant Prostate Cancer Receiving Bipolar Androgen Therapy.

Authors:  Mark C Markowski; Pedro Isaacsson Velho; Mario A Eisenberger; Martin G Pomper; Kenneth J Pienta; Michael A Gorin; Emmanuel S Antonarakis; Samuel R Denmeade; Steven P Rowe
Journal:  J Nucl Med       Date:  2021-01-15       Impact factor: 10.057

6.  Theranostics in Oncology-Thriving, Now More than Ever.

Authors:  Rudolf A Werner; Takahiro Higuchi; Martin G Pomper; Steven P Rowe
Journal:  Diagnostics (Basel)       Date:  2021-04-29

Review 7.  Narrative review of generative adversarial networks in medical and molecular imaging.

Authors:  Kazuhiro Koshino; Rudolf A Werner; Martin G Pomper; Ralph A Bundschuh; Fujio Toriumi; Takahiro Higuchi; Steven P Rowe
Journal:  Ann Transl Med       Date:  2021-05

8.  Prospective Comparison of PET Imaging with PSMA-Targeted 18F-DCFPyL Versus Na18F for Bone Lesion Detection in Patients with Metastatic Prostate Cancer.

Authors:  Steven P Rowe; Xin Li; Bruce J Trock; Rudolf A Werner; Sarah Frey; Michael DiGianvittorio; J Keith Bleiler; Diane K Reyes; Rehab Abdallah; Kenneth J Pienta; Michael A Gorin; Martin G Pomper
Journal:  J Nucl Med       Date:  2019-08-26       Impact factor: 10.057

Review 9.  New imaging modalities to consider for men with prostate cancer on active surveillance.

Authors:  Yasin Bhanji; Steven P Rowe; Christian P Pavlovich
Journal:  World J Urol       Date:  2021-06-19       Impact factor: 4.226

10.  Prostate-specific membrane antigen positron emission tomography (PSMA-PET) for local staging of prostate cancer: a systematic review and meta-analysis.

Authors:  Sungmin Woo; Soleen Ghafoor; Anton S Becker; Sangwon Han; Andreas G Wibmer; Hedvig Hricak; Irene A Burger; Heiko Schöder; Hebert Alberto Vargas
Journal:  Eur J Hybrid Imaging       Date:  2020-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.